Intra-abdominal fat is a major determinant of the National Cholesterol Education Program Adult Treatment Panel III criteria for the metabolic syndrome.

By D. Carr, K. Utzschneider, R. Hull, Keiichi Kodama, B. Retzlaff, J. Brunzell, J. Shofer, B. Fish, R. Knopp, S. Kahn. Diabetes, 2004

1,027 citations recorded by the source corpus.

Subfields: Endocrinology, Diabetes and Metabolism, Epidemiology, Public Health, Environmental and Occupational Health

View Paper: https://www.semanticscholar.org/paper/5a6cd27311f3731b8696866b689497b49ac40553

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Endocrinology, Diabetes and Metabolism

1. S. Grundy
2. E. Gale
3. Myung‐Sook Choi
4. S. Daniels
5. U. Jung
6. R. Eckel
7. Ronald M. Krauss
8. Gerald I. Shulman

In Epidemiology

1. S. Grundy
2. Myung‐Sook Choi
3. G. Iacobellis
4. U. Jung
5. R. Eckel
6. Gerald I. Shulman
7. V. Samuel

In Public Health, Environmental and Occupational Health

1. S. Daniels
2. D. Morbeck
3. S. Grundy

Citations in the corpus

• Defining high-fat-diet rat models: metabolic and molecular effects of different fat types. (2006, methodology): “Weight, food intake, whole-body insulin tolerance and plasma parameters of glucose and lipid metabolism were measured during a 12-week diet course.”
• Diagnosis and management of the metabolic syndrome (2005, background): “type 2 diabetes mellitus in first-degree relatives before age 60 years,109 (2) polycystic ovary disease,9 (3) fatty liver,135 (4) C-reactive protein (CRP) 3 mg/L (if measured),96 (5) microalbuminuria (if detected),136–141 (6) impaired glucose tolerance (if measured),109 and (7) elevated total apoB (”
• Fat Tissue, Aging, and Cellular Senescence (2010, background): “Visceral fat enlargement is more strongly associ- ated with ectopic fat deposition, lipotoxicity, and metabolic disease than generalized obesity, especially in old age (Carr et al., 2004; Tchkonia et al., 2006a; Wannamethee et al., 2007; Gustafson et al., 2009; Thomou et al., 2010).”
• The metabolic syndrome: time for a critical appraisal (2005, neutral): “for some of the syndrome factors is related to abnormalities in visceral adipose tissue [152] or an altered inflammatory state; other factors may be associated with the cluster because they relate indirectly to one of its components.”
• A multisociety Delphi consensus statement on new fatty liver disease nomenclature (2023, neutral): “First, the key metabolic dysfunction underlying MASLD is insulin resistance, and the selected metabolic risk factors do not equally predict insulin resistance, as, for example, diastolic blood pressure and HDL-C are only weakly associated with insulin resistance [18].”
• Obesity and Its Metabolic Complications: The Role of Adipokines and the Relationship between Obesity, Inflammation, Insulin Resistance, Dyslipidemia and Nonalcoholic Fatty Liver Disease (2014, background): “Obesity, especially abdominal obesity, is one of the predominant underlying risk factors for metabolic syndrome [4].”
• Diagnosis and Management of the Metabolic Syndrome: An American Heart Association/National Heart, Lung, and Blood Institute Scientific Statement (2005, background): “type 2 diabetes mellitus in first-degree relatives before age 60 years,109 (2) polycystic ovary disease,9 (3) fatty liver,135 (4) C-reactive protein (CRP) 3 mg/L (if measured),96 (5) microalbuminuria (if detected),136–141 (6) impaired glucose tolerance (if measured),109 and (7) elevated total apoB (”
• Epicardial adipose tissue: anatomic, biomolecular and clinical relationships with the heart (2005, background): “Thus, the increased accumulation of visceral fat is now widely seen as a defining characteristic of the so-called metabolic syndrome”
• The metabolic syndrome: useful concept or clinical tool? Report of a WHO Expert Consultation (2010, background): “There is no accepted central underlying mechanism, although insulin resistance [3] and central obesity [11] have both been proposed in this role.”